OptimizeRx (OPRX) Competitors $12.50 -0.12 (-0.95%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$12.50 -0.01 (-0.04%) As of 08/1/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OPRX vs. IIIV, IBTA, FVRR, RSKD, UXIN, PRSU, PSFE, CARS, NEO, and NRDSShould you be buying OptimizeRx stock or one of its competitors? The main competitors of OptimizeRx include i3 Verticals (IIIV), Ibotta (IBTA), Fiverr International (FVRR), Riskified (RSKD), Uxin (UXIN), Pursuit Attractions and Hospitality (PRSU), Paysafe (PSFE), Cars.com (CARS), NeoGenomics (NEO), and NerdWallet (NRDS). These companies are all part of the "business services" industry. OptimizeRx vs. Its Competitors i3 Verticals Ibotta Fiverr International Riskified Uxin Pursuit Attractions and Hospitality Paysafe Cars.com NeoGenomics NerdWallet i3 Verticals (NASDAQ:IIIV) and OptimizeRx (NASDAQ:OPRX) are both small-cap computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings. Do analysts prefer IIIV or OPRX? i3 Verticals currently has a consensus target price of $29.57, indicating a potential upside of 5.61%. OptimizeRx has a consensus target price of $10.81, indicating a potential downside of 13.50%. Given i3 Verticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe i3 Verticals is more favorable than OptimizeRx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score i3 Verticals 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86OptimizeRx 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.73 Does the media refer more to IIIV or OPRX? In the previous week, i3 Verticals had 1 more articles in the media than OptimizeRx. MarketBeat recorded 4 mentions for i3 Verticals and 3 mentions for OptimizeRx. i3 Verticals' average media sentiment score of 1.08 beat OptimizeRx's score of 0.78 indicating that i3 Verticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment i3 Verticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OptimizeRx 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in IIIV or OPRX? 84.2% of i3 Verticals shares are owned by institutional investors. Comparatively, 76.5% of OptimizeRx shares are owned by institutional investors. 59.1% of i3 Verticals shares are owned by insiders. Comparatively, 5.6% of OptimizeRx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger earnings & valuation, IIIV or OPRX? i3 Verticals has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than i3 Verticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratioi3 Verticals$229.92M4.05$113.34M$4.406.36OptimizeRx$92.13M2.51-$18.66M-$0.84-14.88 Which has more risk & volatility, IIIV or OPRX? i3 Verticals has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Is IIIV or OPRX more profitable? i3 Verticals has a net margin of 46.46% compared to OptimizeRx's net margin of -16.33%. i3 Verticals' return on equity of 3.15% beat OptimizeRx's return on equity.Company Net Margins Return on Equity Return on Assets i3 Verticals46.46% 3.15% 2.00% OptimizeRx -16.33%-0.29%-0.20% Summaryi3 Verticals beats OptimizeRx on 15 of the 17 factors compared between the two stocks. Get OptimizeRx News Delivered to You Automatically Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPRX vs. The Competition Export to ExcelMetricOptimizeRxCOMP IndustryComputer SectorNASDAQ ExchangeMarket Cap$233.41M$172.57B$29.13B$9.52BDividend YieldN/A1.30%3.08%4.09%P/E Ratio-14.8838.1648.1323.81Price / Sales2.519.761,544.8266.04Price / CashN/A29.1138.0757.96Price / Book1.9710.347.415.54Net Income-$18.66M$3.72B$782.10M$259.28M7 Day Performance-12.89%-3.52%-3.69%-4.64%1 Month Performance-4.73%-0.15%-0.16%4.41%1 Year Performance29.53%35.39%52,681.95%17.95% OptimizeRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPRXOptimizeRx1.8022 of 5 stars$12.50-1.0%$10.81-13.5%+19.2%$233.41M$92.13M-14.88100News CoverageUpcoming EarningsIIIVi3 Verticals3.8216 of 5 stars$28.89+0.9%$29.57+2.4%+16.1%$951M$229.92M6.571,480Positive NewsUpcoming EarningsIBTAIbotta3.4944 of 5 stars$38.28+3.7%$61.60+60.9%N/A$934.71M$367.25M25.87N/APositive NewsFVRRFiverr International3.4499 of 5 stars$25.83+0.5%$36.00+39.4%-5.2%$920.84M$391.48M54.95790Trending NewsEarnings ReportAnalyst ForecastRSKDRiskified1.5991 of 5 stars$5.61+5.2%$6.03+7.6%-18.9%$859.24M$327.52M-25.48780News CoverageUXINUxin0.581 of 5 stars$4.75+4.2%N/A+121.1%$857.22M$190.40M-23.75810News CoverageShort Interest ↑PRSUPursuit Attractions and Hospitality0.7243 of 5 stars$29.93+0.1%$29.67-0.9%N/A$844.57M$366.49M2.431,500PSFEPaysafe2.9407 of 5 stars$13.77+0.1%$16.95+23.1%-43.7%$823.46M$1.70B-688.453,300Gap DownCARSCars.com3.7828 of 5 stars$12.88+0.0%$18.30+42.1%-37.3%$817.60M$719.15M18.931,800Upcoming EarningsNEONeoGenomics4.1213 of 5 stars$6.21-0.5%$13.83+122.8%-70.5%$803.05M$660.57M-10.182,200Trending NewsAnalyst ForecastNRDSNerdWallet3.0682 of 5 stars$10.41+1.3%$15.00+44.1%-7.9%$765.99M$687.60M26.69770 Related Companies and Tools Related Companies i3 Verticals Alternatives Ibotta Alternatives Fiverr International Alternatives Riskified Alternatives Uxin Alternatives Pursuit Attractions and Hospitality Alternatives Paysafe Alternatives Cars.com Alternatives NeoGenomics Alternatives NerdWallet Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPRX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptimizeRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OPRX Stock Alerts